Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Phase II trial assessing the efficacy of a reduced dose strategy of darunavir to 400 mg/d in
HIV-1 infected patients virologically suppressed under a once daily regimen including
darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain
the viral load lower than 50 copies / mL at 48 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)